Article: ROZEREM(TM) (ramelteon) Showed Significant Reduction in Time to Fall Asleep With No Evidence of Rebound Insomnia or Withdrawal Effects.

Rozerem.(NEW PRODUCTS THIS QUARTER)(Brief Article)
MPR Monthly Prescribing Reference;  November 1, 2005 ;     700+ words ... ... to placebo. Studies indicated that there was no evidence of next-day residual effect (after 2 nights of dosing) or rebound insomnia. Ramelteon is capable of reducing testosterone and cortisol levels and increasing prolactin levels. If unexplained amenorrhea ...

Rozerem.(Hypnotic from Takeda Chemical Industries Ltd for ...
Physician Assistants' Prescribing Reference;  December 22, 2005 ;     700+ words ... ... to placebo. Studies indicated that there was no evidence of next-day residual effect (after 2 nights of dosing) or rebound insomnia. Ramelteon is capable of reducing testosterone and cortisol levels and increasing prolactin levels. If unexplained amenorrhea ...

Article: ROZEREM(TM) (ramelteon) Now Available in U.S. Pharmacies.
PR Newswire;  September 26, 2005 ;     700+ words ... ... North America, Inc. today announced that ROZEREM(TM) (ramelteon) 8-mg tablets are ... characterized by difficulty with sleep onset. ROZEREM is the first prescription insomnia medication ... prescribed for long-term use in adults. ROZEREM is the first and only prescription sleep ...

Article: FDA Approved ROZEREM(TM) (ramelteon), First and Only ...
PR Newswire;  July 22, 2005 ;     700+ words ... ... approved the New Drug Application (NDA) for ROZEREM(TM) (ramelteon) 8-mg tablets for the ... FDA approval allows physicians to prescribe ROZEREM for long-term use in adults. ROZEREM is the first and only prescription sleep medication ...

Article: Study Demonstrated ROZEREM(TM) (ramelteon) Does Not Affect ...
PR Newswire;  June 13, 2007 ;     700+ words ... ... studies presented today demonstrated that ROZEREM did not affect body sway at peak plasma ... data are important because they show that ROZEREM may be a safe sleep medication for the ... patients' memories were not affected by ROZEREM the next morning," said Gary Zammit ...

Article: Ads may jolt pill sales: The FDA approved Takeda Pharmaceuticals' ...
Chicago Tribune (Chicago, IL);  July 16, 2006 ;     700+ words ... ... consumers for its new sleeping pill, Rozerem, which the Food and Drug Administration ... other prescription sleeping aids pose. Rozerem will compete against drugs like Ambien ... about $100 million to launch an array of Rozerem ads, but the company would not confirm ...

Article: AbelsonTaylor Wins 57 Honors in Major Ad Competitions, Claiming ...
PR Newswire;  May 14, 2007 ;     700+ words ... ... campaign materials supporting the sleep drug Rozerem. The 26-year-old agency won a Global Award for Rozerem in the category of exhibit booth design ... World Wide Web (WWW) Health Award for the Rozerem Web site, and two DTC National Advertising ...